Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Gamboa-Cedeño AM, Castillo M, Xiao W, Waldmann TA, Ranuncolo SM.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1437-1448. doi: 10.1007/s00432-019-02909-z. Epub 2019 Apr 2.

PMID:
30941572
2.

Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer.

Knott ME, Minatta JN, Roulet L, Gueglio G, Pasik L, Ranuncolo SM, Nuñez M, Puricelli L, De Lorenzo MS.

J Mol Biomark Diagn. 2016 Jun;1(Suppl 2). pii: 015. Epub 2016 May 20.

3.

Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma.

Chiorazzi M, Rui L, Yang Y, Ceribelli M, Tishbi N, Maurer CW, Ranuncolo SM, Zhao H, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Shaham S, Staudt LM.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3943-8. doi: 10.1073/pnas.1217271110. Epub 2013 Feb 19.

4.

Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.

Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES, Lewis BA.

Blood. 2012 Nov 1;120(18):3756-63. doi: 10.1182/blood-2012-01-405951. Epub 2012 Sep 11.

5.

Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo.

Ranuncolo SM, Ghosh S, Hanover JA, Hart GW, Lewis BA.

J Biol Chem. 2012 Jul 6;287(28):23549-61. doi: 10.1074/jbc.M111.330910. Epub 2012 May 17.

6.

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA.

Blood. 2009 Dec 17;114(26):5315-21. doi: 10.1182/blood-2009-02-204362. Epub 2009 Oct 23.

7.

BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner.

Ranuncolo SM, Wang L, Polo JM, Dell'Oso T, Dierov J, Gaymes TJ, Rassool F, Carroll M, Melnick A.

J Biol Chem. 2008 Aug 15;283(33):22565-72. doi: 10.1074/jbc.M803490200. Epub 2008 Jun 4.

8.

BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.

Ranuncolo SM, Polo JM, Melnick A.

Blood Cells Mol Dis. 2008 Jul-Aug;41(1):95-9. doi: 10.1016/j.bcmd.2008.02.003. Epub 2008 Mar 17.

9.

Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A.

Nat Immunol. 2007 Jul;8(7):705-14. Epub 2007 Jun 10.

PMID:
17558410
10.

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.

Blood. 2007 Sep 15;110(6):2067-74. Epub 2007 Jun 1.

11.

Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.

Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM.

Cancer Invest. 2006 Mar;24(2):126-31.

PMID:
16537180
12.

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A.

Nat Med. 2004 Dec;10(12):1329-35. Epub 2004 Nov 7.

PMID:
15531890
13.

Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Ranuncolo SM, Varela M, Morandi A, Lastiri J, Christiansen S, Bal de Kier Joffé E, Pallotta MG, Puricelli L.

J Neurooncol. 2004 Jun;68(2):113-21.

PMID:
15218947
14.

EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.

Varela M, Ranuncolo SM, Morand A, Lastiri J, De Kier Joffé EB, Puricelli LI, Pallotta MG.

J Surg Oncol. 2004 Apr 1;86(1):34-40.

PMID:
15048678
15.

Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients.

Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L.

Int J Cancer. 2003 Sep 20;106(5):745-51.

16.

Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.

Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffé E, Inés Puricelli L.

Cancer. 2002 Mar 1;94(5):1483-91.

17.

CD44 expression in human gliomas.

Ranuncolo SM, Ladeda V, Specterman S, Varela M, Lastiri J, Morandi A, Matos E, Bal de Kier Joffé E, Puricelli L, Pallotta MG.

J Surg Oncol. 2002 Jan;79(1):30-5; discussion 35-6.

PMID:
11754374
18.

Expression of CD44s and CD44 splice variants in human melanoma.

Ranuncolo SM, Ladeda V, Gorostidy S, Morandi A, Varela M, Lastiri J, Loria D, Del Aguila R, Joffé EB, Pallotta G, Puricelli L.

Oncol Rep. 2002 Jan-Feb;9(1):51-6.

PMID:
11748454
19.

New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes.

Urtreger AJ, Diament MJ, Ranuncolo SM, Del C Vidal M, Puricelli LI, Klein SM, De Kier Joffe ED.

Int J Oncol. 2001 Mar;18(3):639-47.

PMID:
11179499

Supplemental Content

Loading ...
Support Center